Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence.

Stress Urinary Incontinence Clinical Trial

— Reduc@home  

Official title:

Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03985345
• Other study ID #: 6990
• Status: Completed
• Phase: N/A
• Start date: September 2, 2019
• Est. completion date: September 9, 2020

Study information

• Verified date: March 2021
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

After birth, the perineum has to be trained in order to recover its functions.

This study is designed to assess the quality of life evolution with the EMY connected device.

The secondary purposes are to evaluate patient compliance to the EMY probe, to observe the evolution of urine scores over the duration of the trial in order to consider a comparative study thereafter, and to evaluate the interest of using the EMY connected perineal probe in the context of stress urinary incontinence.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: September 9, 2020
• Est. primary completion date: September 9, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women with urinary leakage, at least once a week or more since more than 3 months

• Women aged 18 and over, no upper age limit

• Patient having given birth since 6 months minimum

• Patient able to do an effective voluntary contraction and avoiding abdominal synergy and apnea during contraction (attested by the health professional partner who leads the patient to the study)

• Patient who has responded favorably to a perineal reeducation with at least 2 sessions (attested by the health professional partner who leads the patient to the clinical study), rehabilitation of stress urinary incontinence or mixed incontinence with predominance of stress urinary incontinence

• Signed informed consent form

• Effective contraception throughout the study (declarative)

• The patient must have a smartphone running at least the Android 5 and iOS 8 versions

• The patient must know how to read and write French

Exclusion Criteria:

• Patient practicing any other perineal reeducation during the study period

• Patient with neurological disease or congenital malformation, urinary incontinence or prolapse treated surgically or medically or perineal hypoesthesia or local conditions that prohibit the use of an intravaginal device

• Patient with an urge urinary incontinence or mixed urinary incontinence with a predominance of urgency.

• Contraindication to the use of the medical device

• Patient with Genito-urinary cancer (in the last 5 years)

• Patient with extra-uretral "incontinence" (fistula, ectopic ureter)

• Patient with severe urinary retention

• Patient carrying a sacral neuromodulation case

• Subject in exclusion period (determined by previous or current study)

• Impossibility to give the patient clear information (patient in emergency situation, patient with difficulties for understanding, ...)

• Patient under the protection of justice

• Patient under guardianship or curatorship

• Pregnancy (positive urine test)

• Breastfeeding patient

Related Conditions & MeSH terms

• Enuresis
• Stress Urinary Incontinence
• Urinary Incontinence
• Urinary Incontinence, Stress

Intervention

Device:
• intravaginal device (probe) EMY
Free use of EMY and its mobile application for 10 minutes during 5 different days per week.

Locations

Country	Name	City	State
France	Strasbourg University Hospitals	Strasbourg

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France	FIZIMED

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Contilife questionnaire	A quality of life questionnaire will be used to follow the quality of life evolution for patients with stress urinary incontinence (UI) using the EMY device.	The change of the quality of life will be assessed : completion of Contilife questionnaire at the inclusion visit (Day 0), one month after inclusion visit (Month1), 2 months after inclusion visit (Month2) and 3 months after inclusion (Month3).
Secondary	The patient compliance to the EMY device		Patients will complete the tracking notebook each time they use the EMY device during 3 months of the clinical research study (from inclusion, until visit Month3).
Secondary	The urinary scores		The change in the urinary scores will be assessed. The ICIQ-SF questionnaire will be completed by patients at the inclusion visit (Day0) and on visits Month1, Month2 and Month3.
Secondary	The interest of using the EMY connected perineal device in the context of stress urinary incontinence		The PGI-I questionnaire will be completed at visit Month3 (3 monhs after inclusion visit).
Secondary	The interest of using the EMY connected perineal device in the context of stress urinary incontinence		The questionnaire of interest will be completed at visit Month3 (3 monhs after inclusion visit).